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Abstract: Human T-cell lymphotropic virus type 1 (HTLV-1) is the etiological agent of 
adult  T-cell  leukemia/lymphoma  (ATL),  whereas  the  highly  related  HTLV-2  is  not 
associated with ATL or other cancers. In addition to ATL leukemogenesis, studies of the 
HTLV  viruses  also  provide  an  exceptional  model  for  understanding  basic  pathogenic 
mechanisms  of  virus-host  interactions  and  human  oncogenesis.  Accumulating  evidence 
suggests that the viral regulatory protein Tax and host inflammatory transcription factor 
NF-B  are  largely  responsible  for  the  different  pathogenic  potentials  of  HTLV-1  and 
HTLV-2. Here, we discuss the molecular mechanisms of HTLV-1 oncogenic pathogenesis 
with  a  focus  on  the  interplay  between  the  Tax  oncoprotein  and  NF-B  pro-oncogenic 
signaling. We also outline some of the most intriguing and outstanding questions in the 
fields  of  HTLV  and  NF-B.  Answers  to  those  questions  will  greatly  advance  our 
understanding of ATL leukemogenesis and other NF-B-associated tumorigenesis and will 
help us design personalized cancer therapies. 
Keywords: ATL; IKK; HTLV; immune escape; NF-B; PDLIM2; Tax; transformation; 
tumorigenesis; virus-host interaction; WWOX 
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1. Introduction 
Human T-cell leukemia virus type 1 (HTLV-1) and type 2 (HTLV-2) are closely related human 
retroviruses  that  were  originally  discovered  in  the  early  1980s  [1].  They  have  a  similar  genome 
structure  with  approximately  70%  nucleotide  homology  (Figure  1).  They  also  share  a  common 
mechanism of replication and transmission. But the pathogenic potentials and clinical manifestations 
of these two highly related viruses differ significantly [2]. HTLV-1 is the etiological agent of adult  
T-cell leukemia/lymphoma (ATL), an aggressive and lethal malignancy of CD4
+ T lymphocytes, as 
well as a variety of autoimmune and inflammatory diseases including the neurodegenerative disorder 
tropical  spastic  paraparesis/HTLV-1-associated  myelopathy  (TSP/HAM).  However,  no  significant 
association of HTLV-2 with human malignancies has been demonstrated. Unfortunately, there is still 
no  cure  for  HTLV-1-associated  malignancies  and  no  means  of  assessing  the  risk  of  disease  or 
prognosis in infected people  [3–5].  In addition to the direct  clinical problems  caused by  HTLV-1 
infection, studies of HTLV-1 particularly in comparison with HTLV-2, provide important models for 
understanding  basic  pathogenic  mechanisms  of  host-virus  interaction,  human  oncogenesis,  and 
inflammatory and autoimmune disorders. 
Unlike  animal  oncoretroviruses,  HTLV-1  does  not  carry  a  host-derived  oncogene  or  activate  a 
cellular oncogene through proviral integration [6]. Instead, HTLV-1 encodes a regulatory protein Tax 
that serves as the primary oncogenic mediator [7–9]. Tax not only transforms rodent fibroblasts but 
also immortalizes human primary T cells in vitro [10–13]. Compared to cells transformed by many 
cellular  oncogenes, Tax-transformed cells have an apparently higher resistance to the induction of 
apoptosis  [14].  In  addition,  Tax-transformed  lymphoid  cells  and  fibroblasts  induce  tumors  when 
introduced into immunodeficient mice (nude mice or SCID mice) [10,13,15]. More importantly, the 
HTLV-1 genome without Tax loses its original transforming ability [16],
 whereas Tax transgenic mice 
develop various tumors depending on the type of the promoters used to drive Tax expression [17–23]. 
A  more  recent  study  shows  that  Tax-transduced  human  hematopoietic  stem  cells,  a  preferential  
HTLV-1 reservoir in vivo, acquire the ability to develop CD4
+ T-cell lymphomas in SCID mice [24]. 
Of  note,  Tax-immortalized  lymphocytes  in  vitro  and  Tax-mediated  T-cell  lymphoma  in  animals 
closely  resemble  the  phenotype  of  HTLV-1-transformed  T-cells  and  HTLV-1-induced  ATL, 
respectively [23–25]. Tax is a pleiotropic protein that exploits various cellular machinery and signaling 
pathways to mediate cellular transformation as well as viral replication (Figure 2). Among those host 
machineries,  NF-B  signaling  plays  a  pivotal  role  in  Tax-mediated  transformation  and  ATL 
leukemogenesis.  Viruses 2011, 3                         
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Figure 1. The Human T-cell lymphotropic virus (HTLV) proviral genome. Gag, Pol, and 
Env are viral structural proteins, others are viral regulatory/accessory proteins. Except the 
hbz  gene,  which  is  encoded  by  the  minus  strand  of  the  HTLV  proviral  genome  from  
3‟-LTR, all other genes are encoded by the plus strand under the direction of the 5‟-LTR. 
Of note, the 5‟-LTR is frequently deleted or methylated as disease progresses. In addition, 
the tax gene often undergoes nonsense or missense mutations during the late stages of ATL 
leukemogenesis. Although the Tax protein and the hbz gene induce tumors in transgenic 
mice and p12 shows weak oncogenic activity in vitro [17–23,245,260], none of the viral 
proteins/genes except Tax are required for HTLV-1-mediated tumorigenesis [16,261–263]. 
ORF: open reading frame. 
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Figure 2. Cellular targets of the Tax viral oncoprotein. NF-B, PI3K/AKT and SRF are 
well-known for their roles in various cellular functions, particularly cell survival and cell 
proliferation.  The  JAK/STAT  signaling  pathway  is  activated  indirectly  through 
Tax-dependent cytokine induction, while all other signaling molecules/signaling pathways 
are directly regulated by Tax. SRF: serum response factor.  
 
2. NF-B Signaling Pathways 
2.1. The NF-B Family 
NF-B,  nuclear  factor-B,  is  a  family  of  transcription  factors  that  plays  a  central  role  in  the 
regulation  of  diverse  biological  processes,  including  immune  responses,  development,  cell 
proliferation and survival [26]. Deregulated NF-B has been linked to a variety of human diseases, 
particularly cancers [27]. The NF-B family consists of five closely related DNA binding proteins: 
RelA (p65), RelB, c-Rel, NF-B1/p50 and NF-B2/p52, which function as various homodimers and 
heterodimers to regulate transcription of genes containing B motifs in their promoters [26]. NF-B 
members share a highly conserved 300-amino acid-long N-terminal Rel homology domain (RHD), 
which is responsible for their dimerization, nuclear translocation, DNA binding and also interaction 
with  the  inhibitors  of  NF-B  (IBs)  (Figure  3).  However,  NF-B  family  members  exhibit  major 
differences in their C-terminal sequences as well as in their modes of synthesis. RelA, RelB and c-Rel 
have transactivating domains (TAD) at their C-termini and are synthesized directly as mature forms, 
whereas p50 and p52 lack a TAD and are generated from large precursor proteins, p105 and p100, 
respectively. Interestingly, p105 and p100 contain IB-like sequences in their C-terminal portions and 
function as NF-B inhibitors [28,29]. Processing of p105 and p100 (selective degradation  of their  
C-terminal  IB-like  sequences)  thus  has  two  functions:  to  disrupt  their  IB-like  function  and  to 
generate  mature  NF-B  subunits.  Since  p105  is  constitutively  processed  to  p50  and  is  
usually  completely  degraded  upon  NF-B  stimulation  [30,31],  it  can  be  simply  considered  as  a Viruses 2011, 3                         
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“typical”  IB. On the other hand, p100 processing is tightly controlled and its induction is highly 
signal-dependent [32,33]. 
Figure 3. Schematic representation of members of NF-B and IB families. ARD: ankyrin 
repeat domain; DD: death domain; GRR: glycine-rich region; LZ: leucine zipper; NES: 
nuclear  export  sequence;  NLS:  nuclear  localization  sequences;  PEST:  PEST  containing 
sequence; RHD: Rel homology domain; TAD: transactivating domain. The NF-B family 
can be divided into two subfamilies. One subfamily consists of three members: RelA, RelB 
and  c-Rel;  and  the  other  one  contains  two  members:  NF-B1/p50  and  NF-B2/p52. 
Typical NF-B dimers are usually composed of one member from each subfamily, such as 
RelA/p50  and  RelB/p52,  although  all  NF-B  members  may  form  various  homo-  or  
hetero-dimers.  Of  note,  the  p50  or  p52  homodimers  mainly  function  as  transcription 
repressors due to lack of a TAD. The IB family can be classified into three subfamilies: 
the typical IB proteins (IB and IB), the precursor proteins (p100 and p105) and the 
atypical  IB  proteins  (BCL-3,  IB,  IB  and  IBNS).  The  typical  subfamily  simply 
functions  as  NF-B  inhibitors.  In  addition  to  being  NF-B  inhibitors,  the  precursor 
subfamily  is  also  required  to  generate  the  NF-B  members  p50  and  p52.  The  atypical 
subfamily  may  function  as  a  co-activator  or  co-repressor  of  NF-B  depending  on  the 
situation.  When  binding  to  Bcl-3,  the  p50  or  p52  homodimers  can  also  induce  gene 
transcription. 
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2.2. Pathways Leading to NF-B Activation 
In unstimulated cells, NF-B dimers are usually sequestered in the cytoplasm by IBs such as IB 
and p100. NF-B nuclear translocation and subsequent transcription activation require degradation of 
IBs  or  processing  of  p100  to  generate  p52,  which  represent  two  major  mechanisms  of  NF-B 
activation  [26].  Due  to  the  fundamental  difference  between  inducible  IB  degradation  and  p100 
processing in their signal transduction and biological outcomes, the two mechanisms leading to NF-B 
activation are termed as the canonical (classical) and non-canonical (non-classical) NF-B pathways, 
respectively (Figure 4).  
Canonical NF-B pathway: The canonical pathway can be rapidly activated by a plethora of stimuli 
from  either  outside  or  inside  cells,  such  as  extracellular  antigens  and  inflammation  cytokines  
(e.g.,  tumor  necrosis  factor,  TNF,  a  prototypic  NF-B  stimulus),  cytoplasmic  oxidative  stress  and 
nuclear DNA damage [34]. These stimuli induce assembly of a multimolecular complex that includes 
the  RING-finger  E3  ubiquitin  ligase  TNF  receptor  associated  factor  6  (TRAF6)  or  other  TRAF 
proteins, leading to K63-linked auto-polyubiquitination of TRAF6 [35,36]. The ubiquitinated TRAF6 
recruits and catalyzes K63-linked ubiquitination of the transforming growth factor--activated kinase 1 
(TAK1) and the IB kinase (IKK) complex (the IKK complex consists of two catalytic components, 
IKK1 (IKK) and IKK2 (IKK), and a regulatory component, NEMO (NF-κB essential modulator, 
IKK)), so that TAK1 can phosphorylate and activate IKK [37]. Once activated, IKK phosphorylates 
specific serines within IBs (e.g., IB, S32 and S36; IB, S19 and S23; p105, S927 and S932), 
triggering their K48-linked ubiquitination by the E3 ubiquitin ligase -transducin repeat-containing 
protein (-TrCP) and subsequent degradation by the 26S proteasome [26,27]. NF-B released from 
IBs then translocates into the nucleus to regulate expression of a wide range of genes, particularly 
those  involved  in  cell  proliferation,  survival,  adhesion  and  migration  [34].  In  addition  to  IB 
degradation, many other regulatory mechanisms are also important for canonical NF-B activation, 
such  as  phosphorylation,  prolyl  isomerization  and  acetylation  of  RelA  [26,27].  These  
post-translational  modifications  prevent  RelA  from  binding  to  IB,  facilitate  RelA  to  recruit  the 
transcriptional coactivators CBP/p300, and/or increase the DNA binding activity and protein stability 
of RelA [38–41].  
Non-canonical  NF-B  pathway:  In  contrast  to  the  canonical  pathway,  the  noncanonical  NF-B 
pathway  is  induced  only  by  a  handful  of  stimuli  including  B-cell  activating  factor  (BAFF), 
lymphotoxin  (LT), CD40 ligand (CD40L), TNF-like weak inducer of apoptosis (TWEAK), and 
receptor activator of NF-B ligand (RANKL) [26]. In addition, activation of the noncanonical NF-B 
pathway is slow and depends on protein synthesis of NF-B-inducing kinase (NIK) [32,42]. Although 
its mRNA expression is relatively abundant, the level of NIK protein is normally very low because it is 
constitutively degraded via a TRAF3-dependent mechanism [42,43]. TRAF3 functions as a scaffold 
between NIK and TRAF2, which in turn recruits cellular inhibitors of apoptosis 1 and 2 (c-IAP1/2) 
into  the  NIK  complex.  Within  the  complex,  c-IAP1  or  c-IAP2  acts  as  the  E3  ubiquitin  ligase  to 
mediate NIK polyubiquitination and proteolysis, thereby keeping its abundance below the threshold 
required for its function [44]. In response to noncanonical NF-B stimuli, either TRAF2 and TRAF3 Viruses 2011, 3                         
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or c-IAP1 and c-IAP2 are degraded by the proteasome, resulting in stabilization and accumulation of 
the newly synthesized NIK, thereby allowing NIK proteins to form oligomers and cross-phosphorylate 
each other for their activation [42,43,45–51]. Self-activated NIK in turn activates the IKK complex and 
specifically recruits IKK1 into the p100 complex to phosphorylate p100, leading to p100 ubiquitination 
by the -TrCP E3 ubiquitin ligase and processing by the proteasome to generate p52 [32,52–54]. The 
processed p52 product, together with its NF-B binding partner, translocates into the nucleus to induce 
or  repress  gene  expression.  Moreover,  NIK-activated  IKK  may  also  induce  IB  degradation  to 
activate the canonical NF-B pathway [55].  
Figure 4. NF-B signaling pathways. Although the canonical and non-canonical signaling 
pathways primarily activate the RelA/p50 and RelB/p52 dimers, respectively, all NF-B 
members may be activated by either pathway or both. In fact, the RelA/p50 dimers may be 
sequestered in the cytoplasm by p100 and can be activated through p100 processing. On 
the other hand, NF-B dimers containing p52 may be sequestered in the cytoplasm by 
IB  and  can  be  activated  through  IB  degradation.  Furthermore,  activation  of  the 
canonical  NF-B  signaling  pathway  can  be  induced  through  inducible  degradation  of 
IB, IB and p105, a process similar to the inducible IB degradation, although their 
degradation dynamics can be different. 
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2.3. Termination of NF-B Activation 
Activation of the NF-B pathways is tightly regulated and rapidly curtailed following the initial 
activating  stimulus.  Transient  activation  of  NF-B  is  physiologically  important  because  persistent 
activation can result in deleterious or even fatal conditions, such as acute inflammation, septic shock or 
at a cellular level, inappropriate cell growth and survival leading to cancer [26]. It is therefore not 
surprising that feedback inhibition mechanisms to terminate NF-B activation occur at almost all steps 
in the leading to activation.  
Consistent with the central role of IKK in the activation of both canonical and non-canonical NF-B 
pathways, several mechanisms are employed to inactivate IKK. Once activated, IKK phosphorylates 
itself  and  its  upstream  activators,  such  as  RIP  in  the  canonical  NF-B  pathway  and  NIK  in  the  
non-canonical NF-B pathway, in addition to the IB proteins. The autophosphorylation of the IKK 
catalytic  components  at  their  multiple  C-terminal  serines  is  supposed  to  cause  conformational 
alteration of IKK and phosphatase recruitment, resulting in dephosphorylation of the IKK activation 
loops and IKK inactivation [56]. Phosphorylation of RIP and NIK, similar to IB phosphorylation, 
leads to K48-linked ubiquitination and degradation of these IKK activators [57,58]. The ubiquitination 
of RIP is mediated by A20 (TNFAIP3, TNF-induced protein 3), a known target of NF-B activation 
[59], providing a distinct feedback inhibition mechanism. In addition to functioning as an E3 ubiquitin 
ligase for RIP K48-linked ubiquitination and degradation, A20 exerts at least two additional functions 
to terminate NF-B activation. First it can function as a deubiquitinase (DUB) to remove K63-linked 
ubiquitin  chains  from  multiple  NF-B  signaling  molecules  such  as  TRAF2/6,  RIP,  MALT1  and 
NEMO.  Alternatively,  it  can  block  continuous  K63-linked  ubiquitination  of  these  key  NF-B 
regulators  by  disrupting  the  interaction  between  the  K63  ubiquitin  ligases  TRAF2/6  and  their  E2 
ubiquitin  conjugating  enzymes  Ubc13  and  UbcH5c  [58,60–63].  As  stated  above  and  shown  in  
Figure  4,  K63-linked  ubiquitination  of  NF-B  signaling  molecules  is  critical  for  the  assembly  of 
signaling complexes and subsequent activation of IKK/NF-B. Interestingly, A20 is also a target of 
IKK activation for phosphorylation. In this case, IKK-mediated phosphorylation increases the K63-
specific  DUB  activity  of  A20,  suggesting  another  feedback  inhibition  mechanism  of  IKK/NF-B 
activation [64]. Besides A20, another deubiquitinase termed cylindromatosis (CYLD) also plays an 
important role in the termination of IKK/NF-B activation [65]. Like A20, CYLD is a target gene of 
NF-B activation and can remove K63-linked ubiquitin chains from multiple activated IKK/NF-B 
signaling molecules, including TRAF2/6, RIP, TAK1, NEMO and Bcl-3 [66–68].  
Given  the  role  of  RelA  posttranslational  modifications  in  its  transcriptional  activity,  several 
mechanisms have been reported to reverse these modifications for NF-B termination. For example, 
phosphorylation and acetylation of RelA are reversibly regulated by different phosphatases and histone 
deacetylases (HDACs) [38,39,41,69–72]. Moreover, RelA phosphorylation induced by pro-inflammatory 
cytokines is blocked by a protein called SINK and the DNA binding activity of RelA can be prevented 
by the basic helix-loop-helix (bHLH) transcription factor Twist or RelA-associated inhibitor (RAI) 
through their associations with RelA in the nucleus [73–75]. Interestingly, SINK and Twist are known 
target genes of NF-B activation [73,74], suggesting that feedback inhibition is a common mechanism 
for NF-B termination at different levels. Viruses 2011, 3                         
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The best known and most critical feedback inhibition mechanism is to replenish the pool of IB 
proteins via NF-B activation. Similar to other NF-B repressors, all IB family  members  except 
IB are direct targets of NF-B. In particular, newly synthesized IB enters the nucleus to bind to 
and transport NF-B dimers back to the cytoplasm to reconstitute the status quo ante [76].  
Recent studies indicate that this feedback inhibition mechanism is neither sufficient nor necessary to 
turnoff  NF-B  activation,  at  least  in  certain  situations  [77].  Instead,  ubiquitination-mediated 
degradation of nuclear NF-B provides a more rapid and essential mechanism for NF-B termination. 
In this context, PDZ-LIM domain-containing protein 2, PDLIM2, a ubiquitously expressed nuclear 
protein  with  a  strong  cytoplasmic-nuclear  shuttling  activity,  is  particularly  important.  PDLIM2 
terminates NF-B activation using two distinct but related mechanisms: it not only functions as an E3 
ubiquitin ligase to promote nuclear RelA ubiquitination but also shuttles RelA to the nuclear matrix for 
the proteasome-mediated degradation [78,79]. Importantly, PDLIM2 knockout mice are more sensitive 
to septic shock due to enhanced p65 activation and subsequently augmented production of inflammatory 
cytokines [78]. 
3. HTLV-1 Deregulation of NF-B  
Although tightly controlled in normal cells including T cells, NF-B is constitutively activated in 
both  transformed  and  untransformed  HTLV-1-infected  cells  [80].  Given  the  association  of  NF-B 
activation with tumorigenesis and the oncogenic ability of Tax [27], much effort has been devoted to 
elucidating  the  mechanism  by  which  Tax  persistently  activates  NF-B.  In  fact,  Tax  is  the  first 
pathogenic  agent  shown  to  activate  NF-B,  and  the  studies  on  Tax  have  greatly  advanced  our 
understanding of both physiological and pathogenic activations of NF-B. 
3.1. Tax-Mediated NF-B Activation  
Activation of the canonical NF-B pathway by  Tax: The initial  clue suggesting a role  of the Tax 
oncoprotein in NF-B activation came from the findings that Tax is able to activate the B element in 
the promoter of the interleukin 2 (IL2) receptor alpha (IL-2R) gene and in the long terminal repeat 
(LTR) of the human immunodeficiency virus type 1 (HIV-1) [81–84]. Since then, our knowledge of 
Tax activation of NF-B has increased significantly. We now know that Tax intervenes at multiple 
levels  to  activate  NF-B.  In  the  cytoplasm,  Tax  directly  binds  to  the  IKK  regulatory  component 
NEMO,  via  the  leucine-repeat  motif  of  Tax  and  two  homologous  leucine  zipper  domains  within 
NEMO, and recruits the IKK complex to the perinuclear compartment where IKK is phosphorylated 
and activated [85–88]. The activated IKK in turn phosphorylates IBs (by IKK2) and also RelA (by 
IKK1),  resulting  in  ubiquitination  and  proteasomal  degradation  of  IBs  and  subsequent  nuclear 
translocation of NF-B including the phosphorylated RelA [89]. In the nucleus, Tax recruits RelA as 
well  as  other  cellular  transcriptional  components  into  interchromatin  granules  to  form  discrete 
transcriptional hot spots termed „Tax nuclear bodies‟ for full NF-B transcriptional activation [90,91].  
Currently, the detailed mechanism of how the Tax-IKK interaction activates IKK remains largely 
unknown. Tax does not have kinase activity and cannot directly phosphorylate IKK for its activation. 
Given the dimerization ability of Tax [92,93], one possibility is that through self-dimerization, Tax 
brings different IKK complexes together so that they can cross-phosphorylate and activate each other. Viruses 2011, 3                         
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In  support  of  the  hypothesis,  fusion  of  Tax,  but  not  its  M22  mutant  that  is  defective  in  self-
dimerization, to IKK1 or IKK2 is sufficient for their catalytic activation [94]. Tax may also act as an 
adaptor protein to recruit the IKK complex and its upstream kinase to the perinuclear compartment to 
form a new complex for IKK phosphorylation and activation. In this regard, the mitogen-activated 
protein kinase kinase kinases (MAP3Ks), MEKK1, NIK, Tpl2, and TAK1, have been shown to interact 
with Tax and enhance Tax-mediated IKK activation when over-expressed [95–98]. However, other 
studies suggest  that  none  of  these  kinases  is  required  for  Tax-mediated  IKK  activation  [99–101]. 
Instead, Tax may activate these MAP3Ks for activation of signaling pathways other than IKK/NF-B. 
Another debated issue is the subcellular locations for Tax-mediated IKK activation. Some suggest it  
is  the  centrosome  [102],  while  others  imply  endoplasmic  reticulum  or  Golgi-associated  structures 
[103–106].  
Interestingly, the critical cytoplasmic and nuclear steps of NF-B activation seem to involve two 
distinct  posttranslational  modifications  of  Tax  protein,  K63-linked  ubiquitination  and  sumoylation, 
respectively [107,108]. While the K63-linked ubiquitination of Tax is mediated by the E2 ubiquitin 
conjugating enzyme Ubc13 and E3 ubiquitin ligase TRAF2, 5 or 6 [95,109], the E3 sumo ligase for 
Tax sumoylation has not yet been identified. Both ubiquitination and sumoylation of Tax involve the 
same C-terminal lysines, suggesting exclusive mechanisms for the two modifications [102,107,108]. 
Currently, it remains unclear whether the same Tax proteins undergo two different modifications for 
cytoplasmic-nuclear  shuttling  to  exert  their  cytoplasmic  and  nuclear  functions  in  the  IKK/NF-B 
activation, or whether different Tax proteins are involved in the different modifications and functions. 
A  recent  study  suggests  that  the  same  Tax  molecule  alternatively  undergoes  ubiquitination  at  the 
centrosome or sumoylation at Tax nuclear bodies, and shuttles between these cytoplasmic and nuclear 
compartments [110]. Interestingly, the same study suggests that the ubiquitination and sumoylation of 
Tax also controls the shuttling of NEMO proteins among the centrosome and different Tax nuclear 
bodies  and  facilitates  NEMO  sumoylation  in  Tax  nuclear  bodies  when  over-expressed.  Nuclear 
shuttling and sumoylation of NEMO are key steps for nuclear initiated IKK/NF-B activation such as 
by  DNA  damage,  an  event  particularly  important  for  cancer  biology  and  cancer  treatment  [111]. 
NEMO sumoylation induced by DNA damage triggers NEMO phosphorylation and monoubiquitination, 
which in turn leads to the relocation of NEMO back to the cytoplasm where the IKK-activating kinase 
TAK1 is recruited to phosphorylate IKK for its catalytic activation [111]. Thus, it is interesting to 
examine whether nuclear sumoylation of NEMO happens under HTLV-1 pathogenic conditions and 
whether Tax-induced NEMO sumoylation is also involved in the induction of NEMO ubiquitination, 
TAK1  recruitment  and  IKK  catalytic  activation.  This  idea  may  be  challenged  by  previous  studies 
showing that fusion of the NEMO N-terminus, which is responsible for the NEMO/IKK1/2 interaction 
but lacks the sumoylation or ubiquitination sites [112], to Tax is sufficient to activate IKK/NF-B in 
NEMO deficient cells [94]. In light of this, some studies suggest that Tax-mediated IKK activation is 
independent  of  NEMO  K63-linked  ubiquitination  and  IKK  upstream  kinases  including  TAK1 
[99,100]. Furthermore, Tax-induced NEMO sumoylation actually reduces the ubiquitination of NEMO 
proteins  [110].  Those  studies  strongly  argue  against  the  role  of  NEMO  nuclear  sumoylation  in  
Tax-mediated  IKK  activation.  Alternatively,  Tax-induced  NEMO  sumoylation  may  prevent  the 
nuclear function of NEMO and therefore contribute to the transcriptional activation of NF-B. In this 
regard, it has been reported that NEMO can translocate into the nucleus to repress NF-B-mediated Viruses 2011, 3                         
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gene transcription by competing with RelA for the transcriptional co-activator CBP [113]. 
Besides the ubiquitin and sumo modifications, Tax also undergoes phosphorylation and acetylation 
[114–116]. Although the kinase(s) responsible for Tax phosphorylation remain to be identified and the 
involved  phosphorylation  sites  are  still  controversial  [114,116],  Tax  phosphorylation  seems  to  be 
important for NF-B activation, possibly by contributing to Tax nuclear translocation, and subsequent 
sumoylation and acetylation in the Tax nuclear bodies [115]. Furthermore, the phosphorylation of Tax 
may be involved in Tax binding to the prolyl isomerase Pin1 and subsequent Tax protein stabilization 
[117,118]. Previous studies have shown that Pin1 directly interacts with and stabilizes phosphorylated 
RelA and c-Rel, thereby increasing NF-B activity and promoting oncogenesis [40,119]. Thus, it is of 
interest  to  examine  whether  Tax  recruitment  of  Pin1  stabilizes  RelA  and  other  NF-B  members, 
besides Tax itself. 
Activation  of  the  noncanonical  NF-B  pathway  by  Tax:  In  addition  to  activation  of  the  canonical  
NF-B  pathway,  Tax  induces  the  processing  of  p100  to  yield  p52  for  the  activation  of  the 
noncanonical  NF-B  pathway  [26].  The  induction  of  p100  processing  is  a  hallmark  of  NF-B 
activation by HTLV-1 infection because activation of this alternative pathway usually occurs in B cells 
and lymphoid stromal cells but not in either resting or activated normal T cells [120]. In contrast to the 
physiological processing of p100, which requires the NIK kinase but is independent of NEMO, Tax 
activation  of  the  noncanonical  NF-B  pathway  requires  NEMO  but  is  independent  of  NIK  [120]. 
NEMO is required in this pathogenic process is because it plays an adaptor role in the assembly of the 
Tax/IKK complexes [120], a step also required to activate the canonical NF-B pathway [121,122]. 
However, unlike the canonical Tax/NEMO/IKK complex, which contains both IKK1 and IKK2, the 
noncanonical  Tax/NEMO/IKK  complex  only  contains  IKK1,  but  not  IKK2  [120].  Like  the  NIK 
kinase, the physiological stimulator of p100 processing, Tax not only activates IKK1 but also recruits 
IKK1 (indirectly via NEMO) into the p100 complex. Within the p100 complex, IKK1 phosphorylates 
p100,  leading  to  p100  ubiquitination  and  processing  by  the  -TrCP  ubiquitin  ligase  and  the 
proteasome, respectively [123]. 
3.2. Tax-Independent NF-B Activation  
Obviously, Tax-mediated  IKK activation is a major mechanism contributing to the high NF-B 
activation in HTLV-1-infected cells. However, Tax expression is lost in about 60% of all ATLs during 
the late stages of leukemogenesis because of hypermethylation, deletion of the proviral 5′ LTR, or 
nonsense or missense mutations of the tax gene [8,124–129]. Notably, both canonical and noncanonical 
NF-B  pathways  are  still  strongly  activated  in  HTLV-1-infected  Tax-negative  cells,  suggesting  a  
Tax-independent mechanism [130–132]. Moreover, Tax-independent NF-B activation also happens 
in Tax-positive cells. Several mechanisms may be involved in Tax-independent NF-B activation in 
HTLV-1-infected  T  cells.  It  is  conceivable  that  ligation  of  the  T-cell  receptor  (TCR)  following  
HTLV-1 infection will lead to canonical NF-B activation. However, if it exists, this is only a minor 
and  transient  mechanism,  since  the  TCR  and  its  proximal  signaling  molecules  are  quickly  down-
regulated after antigen ligation [133]. In fact, loss of antigen receptor and its downstream signaling 
molecules  are  characteristic  and  a  contributing  factor  in  malignant  transformation  of  lymphocytes Viruses 2011, 3                         
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mediated by HTLV-1 or directly by the oncogenic NF-B member c-Rel [134–139]. Possibly, the 
positive  feedback  mechanism  is  the  most  promising  one  for  Tax-independent  NF-B  activation. 
Largely through NF-B activation (initially activated by TCR ligation and Tax, and later activated by 
Tax or Tax-independent mechanisms, see discussion below), HTLV-1 infection induces expression of 
many NF-B stimulators and signaling molecules such as TNF, CD40, CD30, and Bcl-3 [140–143]. 
As discussed previously, TNF is the prototypic stimuli of canonical NF-B activation, while CD40 and 
CD30 are potent activators of both canonical and noncanonical NF-B pathways [144,145]. On the 
other hand, Bcl-3 binds to p50 or p52 homodimers and transforms them from transcription repressors 
into activators [27]. Interestingly, CD30 upregulation and its resulting NF-B activation are hallmarks 
of anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma (HL) [145,146]. Other mechanisms 
involved  in  Tax-independent  NF-B  activation  in  HTLV-1-infected  T  cells  may  be  attributed  to 
various stress conditions and epigenetic/genetic alterations caused by HTLV-1 infection. For example, 
DNA damage, a determining factor in tumorigenesis including ATL leukemogenesis [147,148], can 
lead to strong NF-B activation [111]. On the other hand, epigenetic up-regulation of NIK expression 
and  genetic  deletions  of  the  p100  C-terminus  have  recently  been  detected  in  certain  ATL  cells  
[149–151].  While  NIK  is  a  potent  activator  of  both  canonical  and  noncanonical  NF-B  pathways 
[32,55,96], C-terminal deletions of p100 results in constitutive p100 processing and non-canonical  
NF-B activation [32,152,153].  
3.3. Persistent NF-B Activation by HTLV-1 
Unlike the rapid but normally transient activation under physiological conditions, NF-B activation 
in  HTLV-1-infected  cells  is  aberrantly  persistent,  whether  it  is  Tax-dependent  or  -independent  or 
whether it is canonical or noncanonical. A main reason for this abnormal activation is the co-existence 
and cross-activation of different NF-B and NF-B-related signaling pathways. In this way, the tightly 
controlled activation mechanisms of NF-B are inappropriately unleashed and the normal termination 
mechanisms are overridden. Again, the Tax oncoprotein is the primary culprit. First, Tax persistently 
activates IKK through physical interaction, leading to continuous degradation of IB, which controls 
the  early-phase  of  NF-B  activation,  IB  and  p105,  which  controls  the  late-phase  of  NF-B 
activation,  as  well  as  constant  processing  of  p100,  which  controls  another  late-phase  of  NF-B 
activation (noncanonical pathway) [120,154–158]. Second, Tax binds to and increases the stability and 
activity  of  NF-B  and/or  prevents  NF-B  from  binding  to  its  inhibitors  [159–167],  resulting  in  a 
prolonged  and  elevated  activation  of  NF-B.  Third,  Tax  directly  shuts  off  the  mechanisms  that 
terminate  NF-B  activity.  For  example,  Tax  prevents  nuclear  RelA  from  PDLIM2-mediated 
ubiquitination  and  subsequent  degradation,  although  the  cost  is  the  sacrifice  of  Tax  itself  [168]. 
Moreover, Tax binds to and recruits NEMO-related protein (NRP/Optineurin) and TAXBP1 to the 
Golgi-related structures [104]. Although NRP and TAXBP1 are not required for Tax recruit NEMO, 
the  formation  of  a  Tax/NRP/TAXBP1  ternary  complex  disrupts  the  A20/TAXBP1  deubiquitinase 
complex,  therefore  increasing  K63-linked  ubiquitination  of  Tax  and  possibly  also  many  cellular  
NF-B  signaling  molecules.  As  discussed  previously,  K63-linked  protein  ubiquitination  is  a  key 
mechanism for signaling complex assembly and NF-B activation. Fourth, Tax induces expression of 
NF-B members, signaling molecules and activators, particularly  cytokines, which form a positive Viruses 2011, 3                         
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feedback loop of NF-B activation [140–143,159,169–171]. In this way, different NF-B pathways 
can  be  cross-activated.  Canonical  NF-B  activation  induces  expression  of  p100  as  well  as  p100 
processing  inducers  such  as  CD40  to  persistently  activate  the  non-canonical  NF-B  pathway 
[120,140,159].  Non-canonical  NF-B  also  facilitates  canonical  NF-B  activation  by  repressing 
transcription of the WW domain-containing oxidoreductase (wwox) tumor suppressor gene, a specific 
inhibitor of Tax-induced RelA phosphorylation [172]. In addition to NF-B, Tax induces many other 
signaling pathways such as the phosphatidylinositol 3-kinase (PI3K)/AKT and DNA damage signaling 
pathways,  leading  a  reciprocal  enhancement  of  these  pro-oncogenic  pathways  with  NF-B 
[8,27,111,173,174]. It should be pointed out that most of these mechanisms also apply to the persistent 
activation of Tax-independent and -dependent NF-B. 
3.4. Differences between Tax-Dependent and Tax-Independent NF-B Activation by HTLV-1 
Both canonical and noncanonical NF-B signaling pathways are persistently activated in HTLV-1-
infected  cells  regardless  of  Tax  expression.  In  addition  to  the  common  and  distinct  signaling 
mechanisms  for  their  activation,  Tax-dependent  and  -independent  NF-B  pathways  also  involve 
activation of common and distinct NF-B members. NF-B members activated in Tax-expressing T 
cells  are  predominantly  RelA,  c-Rel,  p50  and  p52  [120,159,169],  and  those  in  HTLV-1-infected  
Tax-negative T cells and primary ATL cells are mainly RelA and p50 [131,169]. Consistent with the 
role  of  positive  feedback  mechanisms  in  persistent  NF-B  activation,  expression  of  c-Rel  and 
p100/p52 is induced in Tax-expressing cells while that of p105/p50 mRNA is enhanced in ATL cells 
[159,169–171]. Activation of common and distinct NF-B members leads to transcriptional changes, 
which regulate specific stage of ATL leukemogenesis. For example, c-Rel-mediated activation of IL2 
and  IL2R  may  play  a  critical  role  in  growth,  particularly  the  transition  from  IL2-dependence  to  
IL2-independence, of HTLV-1-infected T cells during the pre-leukemic stage of ATL [175,176]. On 
the  other  hand,  p50-dependent  induction  of  activation-induced  cytidine  deaminase  (AID)  may 
contribute to genomic mutations and ATL initiation and development [177].  
4. NF-B in ATL Leukemogenesis 
4.1. Significance of NF-B in Tax-Mediated Cellular Transformation and ATL Leukemogenesis 
The  significance  of  NF-B  activation  in  ATL  leukemogenesis  has  been suggested  since  it  was 
linked to HTLV-1 induction of the IL2R in the late 1980s [81,83,84]. The requirement of NF-B for  
HTLV-1- or Tax-induced immortalization was largely defined using Tax mutants that are deficient in 
the activation of either NF-B or CREB/ATF (cyclic-AMP-response element binding protein/activating 
transcription  factor),  a  transcription  factor  responsible  for  Tax-mediated  viral  gene  expression 
[178,179].  Surprisingly,  these  Tax  mutant  analyses  have  yielded  conflicting  results  as  to  whether  
NF-B  or  CREB/ATF  activation  is  critical  for  Tax-mediated  cellular  transformation  [180–183]. 
Regardless  of  the  discrepancy,  studies  using  the  Tax  mutants  suggest  that  NF-B  is  important  in  
Tax-induced  IL2-dependent  or  -independent  cell  growth  as  well  as  in  HTLV-1-induced  T-cell 
immortalization [184–187]. In addition, inhibition of NF-B, by silencing NF-B or its activators IKK 
and NIK, by over-expressing degradation/processing-resistant forms of IB and p100, or by using Viruses 2011, 3                         
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IKK/NF-B  chemical  inhibitors,  prevents  Tax-mediated  cellular  transformation  and  blocks  the  
growth  of  HTLV-1-  or  Tax-transformed  cells  and  ATL  cells,  both  in  culture  and  in  SCID  mice 
[80,122,132,150,172,180,188–193]. Together, those studies suggest that NF-B plays a crucial role in  
HTLV-1/Tax-mediated transformation in vitro.  
Recently, an in vivo role of NF-B in HTLV-1-mediated tumorigenesis has been demonstrated in 
two independent studies using two different Tax transgenic mouse models: lymphocyte-restricted Tax 
transgenic mice and HTLV-1 LTR Tax transgenic mice. The former mice develop a lethal cutaneous 
disease that shares several features in common with the skin disease that occurs during the preleukemic 
stage in HTLV-1-infected patients [194], while the latter mice develop different kinds of soft tissue 
tumors  [17,18].  Notably,  mice  expressing  a  Tax  mutant  defective  in  the  activation  of  
NF-B,  but  not  CREB/ATF,  fail  to  develop  the  skin  disease  or  any  other  diseases  [194].  More 
interestingly,  genetic  knockout  of  the  nf-kb2  gene  alone  dramatically  delays  tumor  onset  in  the  
HTLV-1 LTR Tax transgenic mice [172]. These in vivo studies also suggest that both canonical and 
non-canonical  NF-B  pathways  are  involved  in  Tax-induced  cellular  transformation  and 
tumorigenesis.  In  this  regard,  knockdown  of  either  rela  or  nf-kb2  reduces  Tax-induced  T-cell 
proliferation in vitro [195]. On the other hand, the transforming activity of Tax2, the homologous Tax 
protein encoded by HTLV-2, which activates the canonical NF-B pathway as efficiently as Tax but 
loses the ability to activate the noncanonical NF-B pathway, is much lower than that of Tax [196]. 
Induction of p100 processing by expressing the NIK kinase can restore the transforming activity of 
Tax2 to a level comparable to that of Tax [196].  
4.2. Functional Role of NF-B in Tax-Mediated Cellular Transformation and ATL Leukemogenesis  
NF-B has been suggested to be involved in all stages of ATL leukemogenesis from initiation to 
invasion and dissemination, through the transcriptional regulation of various tumor-related genes [27]. 
During the early stages of ATL leukemogenesis, NF-B induces expression of genes involved in T-cell 
proliferation  and  survival  such  as  IL2R,  IL4,  IL6,  IL8,  IL9,  IL13,  IL21,  IL27,  IL15R,  CXCR7,  
MCP-1, CD30, CD40, OX40/OX4OL, miRNA146a, 4-1BB, Bcl-2, Bcl-xL, cIAP, CCD1, CCD2, and 
CCD6  [81,83,84,140,141,195,197–216].  Activated  NF-B  also  promotes  genetic  and  epigenetic 
changes that drive the transformation of HTLV-1-infected T cells via several different mechanisms. 
The first one involves induction of the „mutagenic‟ enzyme AID and the epigenetic mediator DNA 
methyltransferase 1 (DNMT1) [177,217]. The second one depends on transcriptional repression of the 
cell cycle checkpoint regulator p53 and the DNA repair protein -polymerase. This function of NF-B 
occurs indirectly through RelA-mediated sequestration of the transcriptional coactivators CBP/p300, 
leading  to  transcriptional  repression  of  the  bHLH  transcription  factor  c-Myb  and  subsequent 
inactivation  of  c-Myb-mediated  transcription  of  p53  and  -polymerase  [218–220].  Since  the 
competition for limited CBP/p300 proteins is an important mechanism for the mutual repression of 
NF-B and p53 [221–223], CBP/p300 sequestration by RelA may also contribute to the transcriptional 
inactivation of p53 in HTLV-1-infected cells. Indeed, Tax-induced transcriptional repression of p53 
requires IKK-mediated RelA phosphorylation, a modification that is known to promote RelA binding 
to CBP/p300 [224–226]. Tax also induces a physical interaction between RelA and p53, suggesting 
another mechanism for NF-B-mediated p53 inactivation [224]. Consistent with the central role of p53 Viruses 2011, 3                         
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in tumor suppression and the causative role of NF-B in tumorigenesis, NF-B also represses p53 at 
the protein level using two different mechanisms. First, activated IKK directly phosphorylates p53 to 
trigger  p53  ubiquitination  by  the  -TrCP  ubiquitin  ligase  and  degradation  by  the  proteasome  and 
second,  activated  NF-B  induces  expression  of  MDM2,  a  ubiquitin  ligase  well-known  for  p53 
ubiquitination  and  degradation  [227–229].  Although  it  remains  unknown  whether  activation  of 
IKK/NF-B  induces  degradation  of  p53  protein  in  HTLV-1-infected  cells,  these  findings  suggest 
different mechanisms for NF-B-mediated suppression of p53 for HTLV-1 pathogenesis. Furthermore, 
NF-B  may  contribute  to  DNA  damage  and  induction  of  oncogenic  mutations  indirectly  through 
inflammation-mediated  production  of  reactive  oxygen  and  nitrogen  species  (ROS  and  RNS)  [27]. 
Interestingly, NF-B also activates many other pro-oncogenic molecules/signaling pathways such as  
c-Myc and PI3K to induce expression of human telomerase reverse transcriptase  (hTERT) for the 
long-term  proliferation  and  clonal  expansion  of  HTLV-1-infected  cells  that  have  acquired 
chromosomal abnormalities [147,174,230,231]. In addition to its role in the initiation and development 
of ATL, deregulated NF-B induces expression of many genes involved in tumor progression and 
metastasis such as matrix metalloproteinase-9 (MMP-9) [232].  
5. Negative Regulation of Tax 
Given  the  strong  oncogenic  ability  of  Tax  and  its  essential  role  in  viral  transcription,  it  is  not 
surprising  that  this  viral  oncoprotein  is  a  major  target  of  both  humoral  and  cellular  immune  
responses  [233–235].  To  evade  the  host  immune  surveillance,  the  virus  has  evolved  several 
mechanisms that allow Tax to be expressed at the proper time and level. During the late stages of ATL 
leukemogenesis when Tax functions have been completed or taken over by other mechanisms such as 
constitutive  NF-B  activation,  its  expression  is  permanently  silenced  via  genetic  mutations  or 
epigenetic repression. Thus, understanding how Tax is regulated will provide important insights into 
the virus-host interaction, viral latency, ATL leukemogenesis as well as health disparities in HTLV-1 
infection. This is particularly important, given that the majority of HTLV-1-infected persons remain 
lifelong asymptomatic carries and it takes decades for ALT to develop in less than 5% virus carriers.  
5.1. Repression of Tax by Viral Genes 
Besides the tax gene, HTLV-1 also encodes several other regulatory/accessory genes including rex, 
p12, p13, p30 and hbz (Figure 1). Among these gene products, Rex, p30 and HBZ have been reported 
to negatively regulate the expression and/or activity of Tax. Rex binds to and exports the unspliced and 
singly spliced viral RNAs, which encode viral structural proteins (env, gag and pol), from the nucleus 
into the cytoplasm [236,237]. Rex also inhibits splicing of the viral RNAs [238]. In these two ways, 
Rex increases the expression of viral structural proteins at the expense of Tax and itself, because the 
Tax and Rex RNAs are generated by a second splicing event from the singly spliced RNA (Figure 1). 
The p30 protein, on the other hand, inhibits expression of Tax and Rex by trapping the tax/rex doubly 
spliced RNAs in the nucleus [239]. Moreover, p30 blocks Tax-dependent viral gene activation  by 
competing  for  binding  to  the  transcriptional  coactivators  CBP/p300  [240].  HBZ  (HTLV-1  basic 
leucine zipper factor), which is encoded by the minus strand of the HTLV-1 proviral genome from  
3′-LTR, functions in both RNA and protein forms. The hbz RNA promotes T-cell proliferation, and the Viruses 2011, 3                         
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HBZ protein suppresses Tax-mediated viral transcription by sequestering CREB/ATF, the transcription 
factor responsible for Tax activation of the HTLV-1 LTR [241–243]. More recent studies suggest that 
the hbz RNA, but not the HBZ protein, increases Tax expression indirectly by down-regulation of p30 
RNA  [244].  Thus,  the  hbz  gene  regulates  Tax  both  positively  and  negatively,  depending  on  its 
expression form. It should be pointed out that the hbz gene induces T-cell lymphoma in mice when it is 
conditionally expressed in CD4
+ T cells [245]. Currently, it remains unknown which form (RNA or 
protein) of the hbz gene drives tumorigenesis in the transgenic mice. Whereas the RNA form, but not 
the protein form, promotes T-cell proliferation in vitro [241], the function of HBZ protein in Foxp3 
regulation in vitro correlates with the increased CD4
+ Foxp3
+ Treg cells in mice [245]. Thus, it seems 
that both forms of the hbz gene contribute to tumorigenesis in the transgenic mice. However, hbz RNA 
may be the main functional form in HTLV-1-infected cells, given that hbz RNA is strongly expressed 
in ATL cells and human T cells transduced with HTLV-1 molecular clones [246]. In contrast to the 
high level of its RNA form, the level of HBZ protein may be very low in infected persons due to high 
human  immune  responses  toward  HBZ  [247,248].  The  main  function  of  the  hbz  gene  in  ATL 
leukemogenesis  appears  to  be  maintaining  the  outgrowth  of  HTLV-1-transfomed  cells  [241,243], 
because  it  is  not  required  for  HTLV-1-mediated  T-cell  immortalization  [249].  Nevertheless,  these 
findings are exciting, as they shed light on the mechanism of how ATL cells maintain the transformed 
phenotype after Tax is inactivated. 
5.2. Repression of Tax by Cellular Genes  
Apart from the immune responses towards Tax, the mechanism of how Tax is regulated by cellular 
factors has been rarely studied. One report showed that histone deacetylase 1 (HDAC1) associates with 
and  prevents  Tax  from  binding  to  the  transcriptional  coactivator  CBP,  thereby  suppressing  Tax 
activation of viral gene transcription [250]. However, another study suggested that the Tax-HDAC1 
interaction benefits viral gene transcription by removing HDAC1 from the viral promoter [251]. Since 
those studies were performed with over-expressed proteins and in the absence of HTLV-1 infection, 
the physiological significance of this finding needs to be examined.  
More  recently,  a  negative  role  of  PDLIM2  in  Tax  regulation  has  clearly  been  demonstrated. 
Through a specific Tax-binding motif, PDLIM2 directly shuttles Tax from its activation sites to the 
nuclear  matrix  for  ubiquitination-mediated  degradation  when  over-expressed  and  during  HTLV-1 
infection [79,168]. Consistently, PDLIM2 expression inversely correlates with the stability and activity 
of Tax in HTLV-1-transformed T cells [168]. Interestingly, PDLIM2 expression is down-regulated in 
HTLV-I-transformed T  cells and  in primary  ATL  cells  partially due to  methylation of the pdlim2 
promoter [252–254]. Notably, PDLIM2 expression blocks constitutive NF-B activation, and prevents 
in vitro cell growth and in vivo tumorigenesis of Tax-expressing cells and HTLV-1-transformed T 
cells, whereas PDLIM2 knockout enhances the pathogenic processes [79,168]. These studies suggest 
that the balance between PDLIM2 and HTLV-1 may determine ATL leukemogenesis. Given its role in 
terminating  NF-B/RelA  activation  [78],  PDLIM2  may  directly  target  RelA  to  suppress  ATL, 
particularly  during  late  stages  of  leukemogenesis  when  Tax  expression  is lost.  In  support  of  this, 
PDLIM2 expression is epigenetically repressed in several tumors such as breast and colon cancers, and 
expression of exogenous PDLIM2 or re-induction of endogenous PDLIM2 inhibits constitutive NF-B Viruses 2011, 3                         
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activation and suppresses in vitro anchorage-independent growth and in vivo tumor formation of those 
malignant cells [253,254].  
6. Conclusions and Perspectives 
Over the past three decades, significant progress has been made toward understanding the molecular 
mechanism of constitutive NF-B activation and its functional role in Tax-mediated tumorigenesis and 
ATL  leukemogenesis.  These  studies  have  greatly  enhanced  our  knowledge  of  NF-B  signaling 
regulation and NF-B-associated tumorigenesis beyond ATL. However, many key issues have not yet 
been addressed. First, it is largely unknown how IKK is activated by the Tax-IKK interaction and 
whether Tax-independent IKK/NF-B activation in HTLV-1-infected T cells is reminiscent of cellular 
mechanisms such as those induced by cytokines, oxidative stress and genetic stress. Second, there is 
still no convincing evidence for a functional role of NF-B pathways, particularly different NF-B 
family  members,  in  Tax-mediated  tumorigenesis  or  ATL  leukemogenesis.  Most  functional  studies 
have focused on the in vitro effects on Tax-induced cell growth and immortalization using IKK or  
NF-B  inhibitors  (most  of  them  not  completely  NF-B  specific,  and  IKK  has  many  functions 
independent of NF-B activation) or Tax mutants defective in NF-B but not CREB/ATF activation. 
However, Tax has many functions beyond NF-B and CREB/ATF. Moreover, the functions of Tax are 
highly sensitive to structural changes [178,179]. The loss-of-function studies through Tax mutations 
may  be  artificial.  Third,  it  remains  largely  unknown  how  NF-B  cooperates  with  other  signaling 
pathways in tumorigenesis. In this regard, NF-B is known to crosstalk with many other tumor-related 
signaling pathways such as autophagy and PI3K signaling pathways [255–257]. Fourth, most studies 
focus on the net effect of NF-B activation on cell growth and tumor tumorigenesis. As an old Chinese 
saying goes, everything has  yin (negative) and  yang (positive), two opposite aspects, and so does  
NF-B. Although NF-B activation contributes to tumorigenesis in general, it may also play a negative 
role at certain stages of tumorigenesis and even exert a net negative effect on tumorigenesis in certain 
situations. One mechanism  of  NF-B-mediated tumor suppression involves its original function  in 
immunity  and  immunosurveillance  [27].  Moreover,  Tax-activated  NF-B  may  also  lead  to  cell 
apoptosis [258]. Currently, it is largely unknown how the anti-tumor activity of NF-B is suppressed and 
converted to be pro-tumorigenic for ATL development. It is possible that various cytokines/chemokines 
and other factors involved in immune responses also stimulate growth and migration of pre-tumor and 
tumor cells, in addition to immune cells [27]. In this regard, HTLV-1-infected T cells are in a unique 
position, because they are part of the immune system. It is also possible that human immune activation 
may induce Tax expression and reactivate latent HTLV-1, thereby leading to ATL development or 
other viral pathogenesis [259]. Fifth, very few downstream targets of NF-B that play a critical role in 
tumorigenesis have been clearly and comprehensively identified. Sixth, possibly the most important 
and interesting question in the HTLV-1 field is how the Tax oncoprotein and the hbz gene cooperate 
and contribute to the pathogenesis of ATL and other HTLV-1-associated diseases. Finally, there is a 
lack of a systematic analysis of the correlations between ATL development and viral gene expression, 
PDLIM2 repression and NF-B activation. Future genetic studies, particularly those using inducible 
and  conditional  transgenic  mice,  and  computational  modeling  analysis  will  help  to  understand the Viruses 2011, 3                         
 
 
731 
complex and dynamic role of NF-B in ATL leukemogenesis and other human tumors, and help to 
design personalized treatments for cancer patients.  
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